The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma.
 
Nabil F. Saba
Honoraria - American Journal OF Managed Care; AstraZeneca; Coherus Biosciences; Eisai; EMD Serono; Exelixis; Fulgent Pharma; GlaxoSmithKline; Inovio Pharmaceuticals; Merck; Novartis; Taiho Pharmaceutical; TOSK; vaccinex
Consulting or Advisory Role - Akeso Biopharma; Fulgent Pharma; GlaxoSmithKline; Seagen
Research Funding - Bristol-Myers Squibb; Exelixis
Patents, Royalties, Other Intellectual Property - Springer textbook Royalty; Uptodate chapter writing and editing
Travel, Accommodations, Expenses - Merck
 
Kevin Joseph Harrington
Honoraria - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Codiak Biosciences (Inst); Inzen Therapeutics (Inst); Johnson and Johnson (Inst); Merck Serono (Inst); MSD (Inst); Nanobiotix (Inst); Oncolys BioPharma (Inst); Pfizer (Inst); Replimune (Inst); Scenic Biotech
Consulting or Advisory Role - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Inzen Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Nanobiotix (Inst); Oncolys BioPharma (Inst); Replimune (Inst)
Speakers' Bureau - BMS (Inst); Merck Serono (Inst); MSD (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Replimune (Inst)
 
Lisa F. Licitra
Honoraria - Adlai Nortye; ALTIS Omnia Pharma Service S.r.l.; Bristol Mayers Squibb [K.K.]; Merck KGaA; Merck Serono; MSD IT
Consulting or Advisory Role - Abbvie S.r.l.; ALX Oncology; AstraZeneca; Boehringer Ingelheim; Eisai; EMD Ser Reaserach & Development Institute Inc.; Genmab; GlaxoSmithKline; GroupH Ltd; Janssen Research & Development; Merck Healtcare KGaA; Merck Serono; Mirati Therapeutics; MSD; MSD; Novartis Farma S.p.a.; Roche; Seagan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); IRX Therapeutics (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - TAE Life Sciences
 
Jean-Pascal H. Machiels
Consulting or Advisory Role - ALX Oncology; Astellas Pharma (Inst); AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CUE Biopharma; CureVac (Inst); eTHERNA; F-star; Genmab (Inst); GlaxoSmithKline (Inst); Incyte; Innate Pharma; ITeos Therapeutics; Janssen; Merck Serono; Merus (Inst); MSD Oncology (Inst); NEKTAR; Novartis; Pfizer; Roche; Seagen (Inst); Seagen (Inst)
Research Funding - Bayer; Janssen; Novartis; Sanofi
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Gilead Sciences; Merck Serono (Inst); MSD; Pfizer
Other Relationship - PsiOxus Therapeutics
 
Mei Huang
Employment - Exelixis; Sierra Oncology
Stock and Other Ownership Interests - Exelixis; Sierra Oncology
Patents, Royalties, Other Intellectual Property - Sierra Oncology
 
Fiona Xu
Employment - Exelixis
 
Pritesh Patel
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Robert I. Haddad
Employment - Dana-Farber Cancer Institute
Leadership - NCCN
Stock and Other Ownership Interests - tosk
Consulting or Advisory Role - ALX Oncology; AstraZeneca; aveo; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Coherus Biosciences; Eisai; EMD Serono; Galera Therapeutics; Genmab; GlaxoSmithKline; Merck; Merus; PDS Biotechnology; Scholar Rock
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Kura Oncology (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Boehringer Ingelheim; Hookipa Pharma; ISA Pharmaceuticals; Nanobiotix